Announcement includes Paragon's BioPark facilities expanding to encompass an additional 10,000-square-feet of space 

BALTIMORE, Jan. 23, 2018 /PRNewswire/ -- Paragon Bioservices (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces the expansion of a new process development and cGMP manufacturing facility located conveniently near Baltimore/Washington International Thurgood Marshall (BWI) Airport. Growing need for broad gene therapy manufacturing capacity from its current and future client base is driving the company's investment in this new facility, which the company expects will include commercial manufacturing capabilities in 18 to 24 months.

The company currently provides full process and analytical development and cGMP clinical manufacturing services for a large and diverse, global customer base from its 80,000 square-foot facility in the University of Maryland's BioPark located in Baltimore City. Paragon's current cGMP facilities, which include mammalian, microbial and virus suites, as well as automated aseptic fill-finish capabilities, will also be expanded to encompass an additional 10,000-square-feet of space within the BioPark.

"The expansion of our biopharmaceutical manufacturing capabilities via our new site, including the ability for commercial manufacturing, is a key strategic initiative for Paragon," said Pete Buzy, President and CEO. "Paragon is one of the few gene therapy manufacturers that has the expertise to develop and successfully manufacture complex biotherapeutics using commercially-scalable processes. We have become a center of excellence for both gene therapy and novel vaccine manufacturing and are trusted by top biopharmaceutical companies."​

Click here to read the full release on the Paragon Bioservices website.